CTTH - CTT Pharma Announces South Africa Patent Approval
(TheNewswire)
Tampa, Florida, United States –TheNewswire - March 22, 2022 - CTT Pharmaceutical Holdings,Inc . ( OTC: CTTH) has expanded its reach into additional internationalmarkets with a successful patent application of its Oral Strip drugdelivery system in South Africa. This patent covers our "OralStrip" delivery system, which utilizes micelles to deliveraccurate and reliable active ingredient dosages rapidly. Theapplication of micelles in drug delivery is a powerful alternative fordissolving hydrophobic drugs in aqueous environments, minimizing drugdegradation and loss, preventing harmful side effects, and increasingdrug bioavailability. This granted patent is ideal for variousmedical APIs, including cannabinoids, psychedelics, nicotine, etc.,for the market in South Africa. By increasing our geographicfootprint, CTT Pharma continues to pursue its new strategy ofmonetizing its IP through partnerships for its drug deliverytechnology in many of the world's most rapidly growingmarkets.
"We have over 50 patents pendingworldwide and understand that these patents will also allow us toexpand our reach worldwide, making CTT Pharmaceuticals a globalcompany," said Ryan Khouri, CEO.
CTT is a drug delivery technologycompany that successfully received Health Canada approval, after whichit brought its first product to market as cannabinoid-infused"Dissolve Strips". This successful launch sold out to only85,000 medical patients online with no advertising in severalweeks.
CTT common shares trade on the OTCmarket in the United States under thesymbol "CTTH".
Contact Ryan Khouri at 813-606-0060
Rkhouri@cttpharmaceuticals.com
Copyright (c) 2022 TheNewswire - All rights reserved.